Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1972 1
1973 1
1975 1
1976 1
1977 1
1978 1
1982 1
1984 2
1987 2
1990 1
1991 2
1992 3
1993 1
1994 3
1995 2
1997 2
1998 1
1999 1
2000 1
2001 2
2003 1
2004 3
2005 3
2006 1
2007 3
2008 2
2009 3
2010 3
2011 2
2012 4
2013 6
2014 8
2015 9
2016 5
2017 11
2018 11
2019 6
2020 5
2021 15
2022 4
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
MicroRNAs and angiosarcoma: are there promising reports?
Modarresi Chahardehi A, Afrooghe A, Emtiazi N, Rafiei S, Rezaei NJ, Dahmardeh S, Farz F, Naderi Z, Arefnezhad R, Motedayyen H. Modarresi Chahardehi A, et al. Front Oncol. 2024 May 17;14:1385632. doi: 10.3389/fonc.2024.1385632. eCollection 2024. Front Oncol. 2024. PMID: 38826780 Free PMC article. Review.
Notably, angiosarcoma, along with various other cardiovascular tumors such as lipomas, rhabdomyomas, hemangiomas, and myxomas, has shown variations in the expression of specific miRNA subtypes. ...It comprehensively covers diagnostic methods, prognostic evaluations, and po …
Notably, angiosarcoma, along with various other cardiovascular tumors such as lipomas, rhabdomyomas, hemangiomas, and myxomas, has sh …
Cardiac Rhabdomyomas Presenting with Critical Cardiac Obstruction in Neonates and Infants: Treatment Strategies and Outcome, A Single-Center Experience.
Ng LY, McGuinness J, Prendiville T, Franklin O, Walsh M, Kenny D, Nolke L, McMahon CJ. Ng LY, et al. Pediatr Cardiol. 2024 Jun;45(5):1132-1141. doi: 10.1007/s00246-024-03420-0. Epub 2024 Mar 13. Pediatr Cardiol. 2024. PMID: 38480570 Free PMC article.
Cardiac rhabdomyomas are the most common benign pediatric heart tumor in infancy, which are commonly associated with tuberous sclerosis complex (TSC). ...We present the outcomes of neonates and an infant who received treatment for symptomatic rhabdomyomas at a terti …
Cardiac rhabdomyomas are the most common benign pediatric heart tumor in infancy, which are commonly associated with tuberous scleros …
Mammalian target of rapamycin inhibitors: A new-possible approach for in-utero medication therapy.
Qaderi S, Javinani A, Blumenfeld YJ, Krispin E, Papanna R, Chervenak FA, Shamshirsaz AA. Qaderi S, et al. Prenat Diagn. 2024 Jan;44(1):88-98. doi: 10.1002/pd.6492. Epub 2024 Jan 4. Prenat Diagn. 2024. PMID: 38177082 Review.
In this context, we delve into the potential of mTOR inhibitors as in-utero therapy for fetal abnormalities, with a primary focus on lymphatic malformation (LM) and cardiac rhabdomyoma (CR). While preliminary reports underscore the efficacy of mTOR inhibitors for the treat …
In this context, we delve into the potential of mTOR inhibitors as in-utero therapy for fetal abnormalities, with a primary focus on lymphat …
Long-term use of everolimus for refractory arrhythmia in a child with tuberous sclerosis complex.
Hofmann C, Syrbe S, Hebe J, Kreft J, Stark S, Milde T, Völkers M, Hoffmann GF, Gorenflo M, Kovacevic A. Hofmann C, et al. Am J Med Genet A. 2024 May;194(5):e63508. doi: 10.1002/ajmg.a.63508. Epub 2023 Dec 21. Am J Med Genet A. 2024. PMID: 38130096
Tuberous sclerosis complex is associated with the occurrence of cardiac rhabdomyomas that may result in life-threatening arrhythmia unresponsive to standard antiarrhythmic therapy. ...Intermediate attempts to discontinue everolimus resulted in rhabdomyoma size rebou …
Tuberous sclerosis complex is associated with the occurrence of cardiac rhabdomyomas that may result in life-threatening arrhythmia u …
Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
Yeşil Ş, Kurucu B, Hamamcı MB, Yılmaz Ş, Şahin G. Yeşil Ş, et al. Childs Nerv Syst. 2024 Mar;40(3):831-837. doi: 10.1007/s00381-023-06218-2. Epub 2023 Nov 10. Childs Nerv Syst. 2024. PMID: 37947859
METHODS: In this study, we conducted a retrospective analysis of clinical findings and treatment data from 38 patients diagnosed with tuberous sclerosis who were followed up in the Pediatric Oncology Clinic between 2010 and 2020. ...CONCLUSION: The utilization of mTOR inhi …
METHODS: In this study, we conducted a retrospective analysis of clinical findings and treatment data from 38 patients diagnosed with …
Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma.
Maász A, Bodó T, Till Á, Molnár G, Masszi G, Labossa G, Herbert Z, Bene J, Hadzsiev K. Maász A, et al. Int J Mol Sci. 2023 Aug 17;24(16):12886. doi: 10.3390/ijms241612886. Int J Mol Sci. 2023. PMID: 37629066 Free PMC article.
We present a three-year follow-up of a patient with TSC-associated rhabdomyoma detected in utero. Genetic examination of the fetus and the parents revealed a de novo variant in the TSC2 gene (c.3037delG, p.Asp1013IlefsTer3). ...
We present a three-year follow-up of a patient with TSC-associated rhabdomyoma detected in utero. Genetic examination of the fetus an …
Paradigm shift in the treatment of tuberous sclerosis: Effectiveness of everolimus.
Previtali R, Prontera G, Alfei E, Nespoli L, Masnada S, Veggiotti P, Mannarino S. Previtali R, et al. Pharmacol Res. 2023 Sep;195:106884. doi: 10.1016/j.phrs.2023.106884. Epub 2023 Aug 6. Pharmacol Res. 2023. PMID: 37549757 Free article. Review.
In the past, various therapeutic approaches, even if only symptomatic, have been attempted to improve the clinical effects of this disease. While all of these therapeutic strategies are useful and are still used and indicated, they are symptomatic therapies based on the in …
In the past, various therapeutic approaches, even if only symptomatic, have been attempted to improve the clinical effects of this di …
Cardiac rhabdomyomas: clinical progression, efficacy and safety of everolimus treatment.
Yıldırım S, Aypar E, Aydın B, Akyüz C, Aykan HH, Ertuğrul İ, Karagöz T, Alehan D. Yıldırım S, et al. Turk J Pediatr. 2023;65(3):479-488. doi: 10.24953/turkjped.2022.922. Turk J Pediatr. 2023. PMID: 37395967 Free article.
BACKGROUND: Primary cardiac tumors are extremely rare. Cardiac rhabdomyoma is the most common primary cardiac tumor. 50-80% of solitary rhabdomyomas and all multiple rhabdomyomas are associated with tuberous sclerosis complex. ...Everolimus, a mechanistic tar …
BACKGROUND: Primary cardiac tumors are extremely rare. Cardiac rhabdomyoma is the most common primary cardiac tumor. 50-80% of solita …
Childhood tuberous sclerosis complex in southern Sweden: a paradigm shift in diagnosis and treatment.
Pearsson K, Björk Werner J, Lundgren J, Gränse L, Karlsson E, Källén K, Eklund EA, Bekassy Z. Pearsson K, et al. BMC Pediatr. 2023 Jun 29;23(1):329. doi: 10.1186/s12887-023-04137-4. BMC Pediatr. 2023. PMID: 37386496 Free PMC article.
AIM: To investigate the complete clinical spectrum of individuals with paediatric tuberous sclerosis complex in southern Sweden and explore changes over time. METHODS: In this retrospective observational study, 52 individuals aged up to 18 years at the study start were fol …
AIM: To investigate the complete clinical spectrum of individuals with paediatric tuberous sclerosis complex in southern Sweden and e …
Effect of different dose regimens of everolimus in a series of neonates with giant cardiac rhabdomyomas.
Babaoğlu K, Başar EZ, Usta E, Yılmaz EH, Günlemez A. Babaoğlu K, et al. Cardiol Young. 2023 Nov;33(11):2291-2296. doi: 10.1017/S1047951123000094. Epub 2023 Jan 27. Cardiol Young. 2023. PMID: 36704973
Everolimus is a mTOR inhibitor that has been increasingly used in high-risk cardiac rhabdomyomas in recent years. There are questions regarding the optimal dose and duration of therapy with everolimus for cardiac rhabdomyomas. ...Cardiac rhabdomyoma diagnosis …
Everolimus is a mTOR inhibitor that has been increasingly used in high-risk cardiac rhabdomyomas in recent years. There are questions …
132 results